ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE
El-Bassiouny, N., Kassem, A., Abd-Alhaseeb, M., Tolba, M. (2022). ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE. EKB Journal Management System, 45(2), 801-809. doi: 10.21608/bfsa.2022.271642
Noha A. El-Bassiouny; Amira B. Kassem; Mohammad M Abd-Alhaseeb; Marwa Kamal Tolba. "ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE". EKB Journal Management System, 45, 2, 2022, 801-809. doi: 10.21608/bfsa.2022.271642
El-Bassiouny, N., Kassem, A., Abd-Alhaseeb, M., Tolba, M. (2022). 'ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE', EKB Journal Management System, 45(2), pp. 801-809. doi: 10.21608/bfsa.2022.271642
El-Bassiouny, N., Kassem, A., Abd-Alhaseeb, M., Tolba, M. ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE. EKB Journal Management System, 2022; 45(2): 801-809. doi: 10.21608/bfsa.2022.271642

ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE

Bulletin of Pharmaceutical Sciences Assiut University
Volume 45, Issue 2, December 2022, Page 801-809  XML PDF (871.03 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2022.271642
View on SCiNiTO View on SCiNiTO
Authors
Noha A. El-Bassiounyorcid 1; Amira B. Kassem1; Mohammad M Abd-Alhaseeb2; Marwa Kamal Tolba email orcid 3
1Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Egypt
2Department of Pharmacology and toxicology, Faculty of Pharmacy, Damanhour University, Egypt
3Clinical pharmacy department, faculty of pharmacy, fayoum universit, fayoum, egypt
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes severe acute respiratory syndrome (SARS). It was discovered in December 2019 in Wuhan, China., which subsequently led to a nationwide outbreak. The World Health Organization included the AstraZeneca  and Sinopharm vaccines for the WHO Emergency Use List on February 16 and May 7, 2021, respectively. Egyptians have gotten 2,623,200 doses of AstraZeneca's COVID-19 vaccination plus  500,000 doses of Sinopharm vaccine. The trial would test the vaccinations' short-term side effects on Egyptian people aged 18 and older. Results: Most symptoms decreased significantly after the second dose when compared to symptoms seen at the first dose .In addition, both doses reduced symptoms significantly compared to the first dose.Interestingly, the desire to sleep appears to significantly increase the side effects again after both doses when compared to the second dose alone. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Conclusion: Mild to moderate side effects are to be expected after the vaccination process because the body's immunomodulatory instructions can lead to negative symptoms. Symptoms include injection site soreness, fever, tiredness, headache, muscle aches, chills, and diarrhoea.. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Training and continuing education are needed to improve universal vaccine acceptance and reduce frequency.
Keywords
Vaccination; AstraZeneca; Sinopharm; Egyptian population
Statistics
Article View: 236
PDF Download: 167